Ragosa Mark, chief financial officer of Kiniksa Pharmaceuticals (KNSA), has been a consistent seller of company stock over the past year, with no open-market purchases recorded in his SEC Form 4 filings. Across 39 transactions spanning roughly 12 months, Mark has disposed of shares worth approximately $6.18 million, all in KNSA. The most recent activity, clustered in April 2026, consists entirely of automatic, non-discretionary events: option exercises (code M) valued at zero, restricted stock grants (code A), and shares withheld to cover tax obligations (code F) totaling roughly $184,575. These filings carry no selling bias on their own, as they reflect compensation mechanics rather than market decisions.
The discretionary selling pattern is more telling. Mark executed six open-market sales (code S) between December 2025 and March 2026, with values ranging from $381,719 to $1.78 million. The largest single-day disposition occurred on December 8, 2025, when he sold $1.78 million in KNSA stock, following option exercises that generated $485,000 in proceeds. Subsequent sales on February 9, 2026 ($772,254 combined) and March 9, 2026 ($1.69 million combined) show a steady cadence of roughly monthly liquidations, with the March sale paired with option exercises worth $759,804. The most recent open-market sale was a $502,680 disposition on January 8, 2026, though the pattern suggests ongoing monetization of equity compensation rather than a reaction to price movements.
Notably, Mark has not acquired a single share through open-market purchases (code P) during the entire period, and his total buy value stands at zero. The absence of buys, combined with the regular sell schedule, indicates a clear net-selling bias. However, the transaction mix—dominated by option exercises, tax withholdings, and grants—suggests these sales are largely tied to the vesting and exercise of equity awards, a routine occurrence for executives. The filings reveal a CFO systematically converting vested options into cash, with no indication of opportunistic timing or concentrated selling pressure beyond the scheduled monthly pattern.
AI-assisted summary